In a striking display of market movements, Arcellx’s stock prices soared by about 80% during premarket trade following the announcement of its acquisition by Gilead Sciences. The transaction, valued at $7.8 billion, is set to add to Gilead’s oncology portfolio. Previously, market analysts were anticipating an acquisition given Arcellx’s promising work in CAR-T therapies. Now, with the formalization of the agreement, Gilead aims to enhance its capacity in treating multiple myeloma, setting a notable benchmark within the sector.
Gilead Sciences, already owning 11.5% of Arcellx’s outstanding shares, had previously expressed interest in developing collaborative efforts in the cell therapy field, dating back to their 2022 partnership. Prior reports have indicated Gilead’s strategic interest in leading the cell therapy landscape, and this acquisition marks another step in that direction. The $115 per share offer from Gilead represents an 87% premium over Arcellx’s last closing price before the announcement. Additionally, a $5 contingent value right (CVR) per share is included, contingent upon Arcellx’s lead therapy, anito-cel, achieving substantial sales benchmarks within the specified timeline.
What Are the Financial Expectations?
This acquisition agreement is mapped out as a tender offer, set to culminate with a second-step merger with consistent terms for shareholders. While Arcellx shares swiftly approached the buyout offer price upon the announcement, Gilead’s own shares saw a slight dip by about 1%, a common market reaction when a company engages in significant financial commitments. Gilead projects this acquisition to become accretive to earnings per share from 2028, following the anticipated Food and Drug Administration (FDA) approval of anito-cel.
How Is the Competitive Landscape Shaped?
Gilead is positioning itself to compete with established players like Johnson & Johnson and Legend Biotech, known for their CAR-T therapy, Carvykti. The acquisition of Arcellx, particularly for its anito-cel therapy targeting relapsed or refractory multiple myeloma, underscores Gilead’s targeted strategy in personalized cancer treatment. Industry competitors have focused on efficacy, safety, and scalable manufacturing capabilities, crucial factors for market success.
In light of this competitive environment, Arcellx’s anito-cel shows a promising edge, having been compared favorably against existing treatments. Analysts are particularly keen on the FDA’s pending evaluation, expected by December 23, 2026, given the promising data Arcellx has released to date.
Throughout the acquisition process, Gilead emphasized the significance of the therapeutic potential of anito-cel and their history in cell therapy collaboration with Arcellx.
“We value this opportunity to enhance our portfolio with Arcellx’s promising CAR-T therapy,” remarked a Gilead spokesperson.
Arcellx’s lead therapy, positioned as strategically significant by Gilead, aligns with the ambitious goals set within its oncology division. Having collaborated since 2022, the integration allows Gilead to consolidate control over a program it has invested in and understands well.
“Anito-cel has the potential to be transformative for multiple myeloma patients,” explained an Arcellx representative.
The market for CAR-T therapies continues to grow, and with Gilead’s acquisition of Arcellx, the landscape appears to be intensifying with competition. The structured all-cash deal demonstrates Gilead’s commitment to capitalizing on Arcellx’s CAR-T innovations, particularly anito-cel. It remains to be seen how Gilead’s integration efforts will unfold and impact their overall market share.
